Skip to content

Free style Libre for diabetes 2 management

Glucose monitoring by Freestyle Libre in patients with Type 2 diabetes mellitus from India A pooled analysis - NILL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/03/083238
Enrollment
1200
Registered
2025-03-24
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications

Interventions

Intervention1: Intervention name: FreeStyle Libre : The FreeStyle Libre system is a professional flash glucose monitoring system approved in India. This system can monitor blood glucose for 14 consec

Sponsors

Abbott Healthcare Pvt.Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged above 18 years with a diagnosis of T2D using Libre for glucose monitoring will be included in the study.

Exclusion criteria

Exclusion criteria: Patients below 18 years as well as patients using continuous glucose monitoring instrument other than Libre will be excluded. Patients having difficulty in handling device and are non-compliant will be excluded

Design outcomes

Primary

MeasureTime frame
Estimate the average TIR across 12-15 centres in patients with Diabetes in India with the help of cross sectional data availableTimepoint: Baseline, 4 weeks

Secondary

MeasureTime frame
Estimate % of patients with diabetes in India achieving recommended TIR targets (in line with customized targets based on comorbidities/ type of diabetes) Estimate average TIR among different patient profiles with T2DM based on 1) comorbidities 2) Age groups 3) Form of pharmacotherapy (Non Insulin, Basal Insulin, MDI) 4) Duration of diabetes Estimating % of patients with T2DM achieving TIR targets based on 1) comorbidities 2) Age groups 3) Form of pharmacotherapy (Non Insulin, Basal Insulin, MDI) 4) duration of diabetesTimepoint: Baseline, 4 weeks

Countries

India

Contacts

Public ContactRoopa Subbaiah

Indegene Private Limited

roopa.subbaiah@indegene.com8884759000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026